480 ARSENAL WAY, WATERTOWN, MA
Reports Second Quarter 2026 Financial Results and Provides Business Update
Prefunded Warrant Exercise - Eloxx Pharmaceuticals Issues 2.5M Shares
Stockholder Actions: Approval of First Amendment to 2018 Equity Incentive Plan
News
News, Material Contracts
Material disclosure
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Entry into a Material Definitive Agreement
Q2
Q1
FY 2025
Notice of Late Filing for Quarterly Report
Notice of Late Filing for Annual Report
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Amended Registration Statement for Securities
Registration of Securities
Definitive Information Statement
Preliminary Information Statement
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
SEC Staff Action Letter
Confidential Treatment Order
Submission Upload
Correspondence